Newsletter Tool

Drug Delivery

This Week

Nov 30, 2022

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

LTS Lohmann leads investment in needle-free delivery specialist

Teva-partnered MedinCell bags $42M loan for long-acting injectable R&D

Spying new horizons, Xeris starts work on subcutaneous version of rare disease drug

Featured

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy

By Nick Paul Taylor

Genentech has kicked off a phase 2a clinical trial to optimize subretinal surgical delivery of OpRegen, a cell therapy that is in development as a treatment for the eye disease geographic atrophy.

LTS Lohmann leads investment in needle-free delivery specialist

By Nick Paul Taylor

LTS Lohmann has thrown its weight behind Micron Biomedical’s push to enable the self-administration of drugs and vaccines without needles, co-leading a series A round and establishing a partnership with the drug delivery specialist.

Teva-partnered MedinCell bags $42M loan for long-acting injectable R&D

By Nick Paul Taylor

MedinCell has secured a €40 million ($42 million) loan from the European Investment Bank (EIB), positioning the Teva-partnered pharma company to develop therapies based on its long-acting injectable drug delivery technology.

Spying new horizons, Xeris starts work on subcutaneous version of rare disease drug

By Nick Paul Taylor

Horizon Therapeutics has teamed up with Xeris Biopharma to create an ultra-concentrated, ready-to-use, subcutaneous formulation of teprotumumab, handing over an upfront payment and offering milestones to get its new partner to apply XeriJect to the molecule.

Bionaut Labs secures $43M for its tiny, drug-carrying robots

By Conor Hale

Bionaut Labs’ fantastic voyage continues, with $43.2 million in new venture capital funding to help build up its tiny robots into machines capable of swimming through the human body.

J&J's nasal spray Spravato bests former AZ drug Seroquel XR in treatment-resistant depression trial

By Fraiser Kansteiner

J&J’s Janssen unit rolled out data from the phase 3b ESCAPE-TRD trial pitting its esketamine spray Spravato against extended-release quetiapine in treatment-resistant depression. Quetiapine was formerly marketed by AstraZeneca as Seroquel before the British drugmaker pawned off the rights to Cheplapharm in late 2019. Seroquel is primarily used to treat schizophrenia and bipolar disorder.

Fierce podcasts

Don't miss an episode

'The Top Line': Celebrating the Fiercest Women in Life Sciences

This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report.

'The Top Line': Fierce Biotech's Cell & Gene Therapy Forum

'Podnosis': Public-private coalitions, how to fix healthcare

Resources

Multimedia

Interactive ASH 2022 Planner | Plan Your Conference Attendance

Plan Your ASH’22 Attendance In No Time | Interactive Planner

Sponsored by: Ferma.AI, a product of ZoomRx

Podcast

Medscape Medical Affairs Thought Leaders in Medical Affairs

How can Medical Affairs divisions bring greater value to their organizations and practitioners every day?

Using Digital Therapies and Patient Engagement to Improve Clinical Outcomes

See how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more.

THE BIODRUG REVOLUTION

Accelerating bioproduction towards high performance and scale

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Catalent Pulmonary & Nasal Delivery Capabilities Sheet

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

The keys to success when switching from vials to prefilled syringes and intravenous to subcutaneous formulations for Biologics

Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes.